How should urinary incontinence be managed in a patient with a scarred, open urethra?

Management of Urinary Incontinence with Scarred Open Urethra

For urinary incontinence with a scarred, open urethra—representing severe intrinsic sphincter deficiency—surgical intervention with an artificial urinary sphincter (AUS) is the preferred definitive treatment, with autologous pubovaginal sling as an alternative when the urethra is fixed and immobile. 1, 2

Understanding the Clinical Context

A scarred, open urethra represents a severely compromised bladder outlet with intrinsic sphincter deficiency (ISD). This anatomic situation typically results from:

• Prior urethral trauma or surgery 1, 3
• Failed anti-incontinence procedures 2
• Radiation-induced urethral damage 1, 4
• Post-prostatectomy complications in men 1

The "open" nature indicates the sphincter mechanism cannot maintain adequate closure pressure, making this a challenging clinical scenario that often requires more aggressive intervention than standard stress incontinence 2, 3.

Initial Conservative Management (Limited Efficacy Expected)

While conservative measures have minimal efficacy in severe ISD with urethral scarring, they should still be attempted before proceeding to surgery:

• Pelvic floor muscle training (PFMT) may provide marginal benefit, though effectiveness is substantially reduced when the urethra is structurally compromised 5, 6
• Behavioral modifications including timed voiding and fluid management can reduce symptom burden but will not address the underlying anatomic defect 5, 7
• Avoid pharmacologic therapy for stress incontinence in this context, as systemic medications are ineffective for sphincteric incompetence 5

Important caveat: If there is a concomitant urgency component (mixed incontinence), antimuscarinic medications or beta-3 agonists may address the urgency symptoms but will not improve the stress component from the scarred urethra 5, 8.

Surgical Management Algorithm

For Women with Scarred, Fixed Immobile Urethra:

First-line surgical option: Autologous pubovaginal sling (PVS) 2

• The PVS is preferred over synthetic midurethral slings when the urethra is fixed and immobile due to scarring 2
• This approach has a long track record of success in severe ISD and refractory cases 2
• Synthetic slings have suboptimal outcomes in this population due to the compromised urethral tissue 2

Alternative consideration: Adjustable retropubic midurethral sling (RMUS) 2

• Offers continued adjustability over time, which may be beneficial in recurrent or refractory cases 2
• Studies show variable success with lower rates than in index patients, but the adjustability feature provides ongoing management options 2

For severe cases with multiple failed surgeries:

• Obstructing autologous sling or bladder neck closure with catheterizable stoma may be necessary 2
• Formal urinary diversion (ileal conduit or continent diversion) is reserved for the most refractory cases 2
• Never use synthetic slings when creating an intentionally obstructing sling due to erosion risk 2

For Men with Post-Prostatectomy Scarred Urethra:

Preferred option: Artificial urinary sphincter (AUS) 1, 4

• AUS is the gold standard for male intrinsic sphincter deficiency, particularly after radiation therapy 1
• Best success rates occur in patients with high Valsalva leak point pressure and unscarred vesicourethral anastomosis 1
• However, in the context of a scarred urethra, careful cuff placement is critical 4

Technical considerations for scarred urethra: 4

• Radiation-induced scarring increases erosion risk (relative risk 2.97) 4
• The transcorporal approach is an independent risk factor for erosion in high-risk, radiated urethras 4
• Atrophic, scarred urethra may require additional soft tissue coverage for appropriate cuff sizing 4

Alternative: Male sling procedures 1

• Less effective than AUS but may be considered in patients refusing or unable to tolerate AUS 1
• Adjustable balloon devices have higher complication rates and explant needs within two years compared to AUS 1

Urethral Bulking Agents (Palliative Option)

Consider only as a temporizing measure or for patients who refuse/cannot tolerate surgery: 1, 2

• Bulking agents (collagen, silicone, carbon-coated beads, polydimethylsiloxane, polyacrylamide hydrogel) are the least invasive but also least effective option 1, 2
• Best outcomes in men occur with high Valsalva leak point pressure, unscarred vesicourethral anastomosis, and no radiation history 1
• In women, bulking agents are appropriate for those with significant comorbidities, preference for less invasive treatment, or as a bridge to more definitive surgery 2
• Expect need for repeat injections and counsel patients accordingly 2
• Polyacrylamide hydrogel shows persistence at 96 months but lower satisfaction than surgical options 2

Managing Concomitant Urethral Stricture

If the scarred urethra also has stricture formation (common in this population):

Address the stricture before or simultaneously with incontinence surgery: 3

• Multiple endoscopic techniques available including urethral dilation or direct vision internal urethrotomy 3
• Some surgeons perform simultaneous AUS implantation at the time of endoscopic stricture management 3
• For refractory strictures, urethroplasty may be necessary before addressing incontinence 9, 10
• Two-stage urethroplasty in prostatectomized patients carries risk of stress incontinence (9/33 had troublesome incontinence after first stage, but only 4/33 had continuing incontinence after second stage) 10

Critical point: Stabilize the stricture before proceeding with anti-incontinence surgery to avoid repeated interventions 3.

Special Considerations and Pitfalls

Radiation History:

• Radiated tissue has poor vascular supply, making it vulnerable to cuff compression and erosion 4
• AUS remains preferred over slings or adjustable balloons in radiated patients, but counsel about higher failure rates 1
• Consider transcorporal approach carefully as it increases erosion risk in radiated urethras 4

AUS Device Longevity:

• Counsel patients that AUS will likely lose effectiveness over time with failure rates of approximately 24% at 5 years and 50% at 10 years 1
• Reoperations are common and expected 1
• Malfunctioning devices can be replaced in the same operative setting if not infected 1

AUS Erosion Management:

• If erosion occurs, explant the device and leave urethral catheter in place for several weeks to allow healing 1, 4
• Do not replace for at least 3 months if infected, and preferably place at different urethral location 1
• Intraoperative management options include urethral catheter alone, in situ urethroplasty, or anastomotic urethroplasty 4

Persistent Incontinence After Surgery:

• Perform repeat history, physical examination, and investigations to determine cause 1
• For AUS: check if device is deactivated or inadequately cycled; use cystoscopy to evaluate cuff coaptation; cross-sectional imaging to rule out fluid leak 1
• Recurrent incontinence after years suggests device failure or urethral atrophy 1

What NOT to Do

• Do not use systemic pharmacologic therapy (antimuscarinics, beta-3 agonists) for stress incontinence from sphincteric incompetence—these are ineffective 5
• Do not use synthetic slings when creating an obstructing sling due to unacceptable erosion risk 2
• Do not proceed with incontinence surgery if active urethral stricture is present without addressing it first 3
• Do not use adjustable balloons or male slings as first-line in radiated patients—AUS is preferred despite higher complication risk 1